文献速递妇科产科

葡萄胎后妊娠滋养细胞肿瘤的超声特征及其与甲氨蝶呤耐药的关系

Sonographic characteristics of post-molar gestational trophoblastic neoplasia at diagnosis and during follow-up, and relationship with methotrexate resistance.
PubMed 文献 · Ultrasound Obstet Gynecol · 2020-10-13

本研究回顾性分析36例葡萄胎后妊娠滋养细胞肿瘤(GTN)患者,描述其诊断时及随访中的超声特征,并评估这些特征与一线甲氨蝶呤(MTX)耐药的相关性。结果显示78%的患者诊断时存在子宫病变,大多数病变在随访中完全消退,中位时间7个月;MTX耐药更常见于子宫肿瘤≥4 cm或全局性病变者。

要点

  • 葡萄胎后GTN诊断时78%存在子宫病变,其中67%为局灶性,11%为全局性。
  • 子宫肿瘤≥4 cm和全局性病变与MTX耐药显著相关。
  • 大多数子宫病变在随访中完全消退,中位消退时间约7个月。

核心结论

  • 葡萄胎后GTN诊断时多数存在子宫病变,且多数病变在随访中完全消退;MTX耐药与子宫肿瘤≥4 cm或全局性病变相关。

主要发现

  • 诊断时8例(22%)无子宫病变,24例(67%)为局灶性病变,4例(11%)为全局性病变。
  • 病变最大直径中位数40.4 mm(IQR 31.3-49.4),26/28(93%)色彩评分3或4,9/28(32%)存在动静脉瘘,4/36(11%)有黄素化囊肿。
  • 随访中88%(21/24)病变完全消退,血管消失中位时间5.8个月(IQR 3.7-9.3),病变消退中位时间6.8个月(IQR 3.7-9.3)。
  • MTX耐药发生于12/31(39%)女性;子宫肿瘤≥4 cm在耐药组占73% vs 非耐药组17%(P=0.008),全局性病变占25% vs 0%(P=0.03)。

临床怎么用

  • 对葡萄胎后GTN患者,超声评估子宫病变大小和范围有助于识别MTX耐药高风险者。

局限性

  • 回顾性设计,样本量较小(36例),部分患者因缺乏结构化超声评估而被排除。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To describe the sonographic characteristics of post-molar gestational trophoblastic neoplasia (GTN) at diagnosis and during follow-up, and to assess their association with methotrexate (MTX) resistance (R) as first-line chemotherapy. METHODS: This was a retrospective study of all women treated for post-molar GTN at Karolinska University Hospital, Stockholm, Sweden, between October 2010 and December 2017, who had undergone expert transvaginal ultrasound assessment ≤ 2 weeks prior to, or ≤ 1 week after, the start of first-line MTX treatment. Women with a detectable uterine lesion were followed up with repeat scans during treatment, as well as after treatment in cases of persistent lesions. The association between MTX-R and sonographic findings at inclusion was assessed. RESULTS: Of 47 eligible women, 36 were included in the analysis after excluding those who had not undergone structured transvaginal ultrasound assessment and those who started treatment at another center. The median age at diagnosis was 33 (interquartile range (IQR), 27-43) years and 35/36 (97%) women were in the FIGO low-risk group (risk score, 0-6). At inclusion, no uterine lesions were found in eight (22%) women, focal lesions in 24 (67%) women and global lesions in four (11%) women. Median maximum lesion diameter was 40.4 (IQR, 31.3-49.4) mm and 26/28 (93%) lesions had a color score of 3 or 4. Arteriovenous fistulas were found in 9/28 (32%) women and theca lutein cysts in 4/36 (11%) women. Four women with GTN lesion at inclusion underwent hysterectomy prior to the first follow-up ultrasound scan and a fifth woman with a growing lesion underwent hysterectomy, which revealed persistent viable trophoblastic tissue. All remaining women reached complete remission and median time to human chorionic gonadotropin normalization was 2.7 (IQR, 1.4-3.7) months. During ultrasound follow-up, 88% (21/24) of lesions resolved completely. Two women with a persisting lesion remained in complete remission. Median time to disappearance of vascularity was 5.8 (IQR, 3.7-9.3) months and median time to resolution of the lesion was 6.8 (IQR, 3.7-9.3) months. MTX-R developed in 12/31 (39%) women. Uterine tumors ≥ 4 cm (73% vs 17%; P = 0.008) and global lesions (25% vs 0%; P = 0.03) were significantly more common in women with compared to those without MTX-R. CONCLUSION: Uterine lesions were detected at the time of diagnosis in 78% of women with post-molar GTN. The vast majority of the lesions resolved completely during follow-up, after a median of 7 months. MTX-R was more common in uterine tumors of 4 cm, or larger, and in global lesions. Copyright © 2020 ISUOG. Published by John Wiley & Sons Ltd.

来源:Ultrasound Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Epstein E, Joneborg U. Sonographic characteristics of post-molar gestational trophoblastic neoplasia at diagnosis and during follow-up, and relationship with methotrexate resistance. Ultrasound Obstet Gynecol. 2020. PMID: 31909527. doi:10.1002/uog.21971

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。